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Abstract 
Background: Serine hydroxymethyltransferase 1 (SHMT1) is a key enzyme in the folate metabolic pathway that 
plays an important role in biosynthesis by providing one carbon unit. SHMT1 C1420T may lead to the abnormal 
biosynthesis involved in DNA synthesis and methylation, and it may eventually increase cancer susceptibility. Many 
epidemiologic studies have explored the association between C1420T polymorphism and the risk of non‑Hodgkin 
lymphoma (NHL), but the results have been contradictory. Therefore, we performed this meta‑analysis to evaluate the 
relationship.
Methods: The meta‑analyses were conducted to evaluate the effect of SHMT1 C1420T polymorphism on NHL risk. 
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association.
Results: Eight studies encompassing 3232 cases and 4077 controls were included. A statistically significant associa‑
tion was found between SHMT1 C1420T polymorphism and NHL risk under the allelic comparison (T vs. C: OR = 1.09, 
95% CI 1.01–1.17); a borderline association was found between SHMT1 C1420T polymorphism and NHL risk under the 
homozygote model (TT vs. CC: OR = 1.18, 95% CI 1.00–1.39) and the dominant model (CT+TT vs. CC: OR = 1.10, 95% 
CI 1.00–1.21).
Conclusion: SHMT1 C1420T polymorphism may be associated with NHL risk, which needs to be validated in large, 
prospective studies.
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Background
In the past 30 years, the incidence of non-Hodgkin lym-
phoma (NHL), a common hematologic malignancy, has 
increased markedly [1, 2]. Generally, there are two major 
types of NHL: B cell lymphomas and T-cell lympho-
mas, with B-cell lymphomas accounting for the majority 
(approximately 85%) of cases. Diffuse large B-cell lym-
phoma (DLBCL) and follicular lymphoma (FL) are two 
major subtypes of B-cell lymphomas [3, 4]. Risk factors 
for NHL include family history, immune dysfunction, 
immune stimulation, and environmental exposures such 
as infection, high doses of radiation and pesticides [5, 6]. 
In addition, although the underlying biological mecha-
nisms involved in NHL remain unidentified, it has been 
shown that chromosomal and genetic alterations, caused 
by the total influence of multiple single nucleotide poly-
morphisms (SNPs) in the genes implicated in various 
molecular pathways, also play an important role in the 
development of NHL [7–9]. For example, folate-metab-
olizing genes play significant roles in the development of 
NHL [8]. Therefore, genetic variability in folate-metabo-
lizing genes may be closely related to NHL risk.
Serine hydroxymethyltransferase (SHMT), a key 
enzyme involved in the folate metabolism, can revers-
ibly catalyze serine and tetrahydrofolate to glycine and 
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5,10-methylenetetrahydrofolate [10]. SHMT has two dis-
tinct isoenzymes, one locating in the cytoplasm (SHMT1) 
and the other locating in mitochondria (SHMT2). 
SHMT1, localized on chromosome 17p11.2 [11], plays 
a key role in inducing gene methylation and DNA syn-
thesis by providing one-carbon atoms for purine, thymi-
dylate, and methionine in the cytoplasm [12]. Abnormal 
methylation and DNA repair systems may cause genome 
instability and lead to overexpression of oncogenes and 
inactivation of tumor suppressor genes [13, 14], which 
closely relate to the occurrence and development of com-
mon tumors [15]. Consequently, abnormally functioning 
SHMT1 can affect cell progression and ultimately cause 
cancer. One SNP has been found at nucleotide 1420 
(C1420T, rs1979277) [16], and it can influence the func-
tion of SHMT1 by a leucine-to-phenylalanine amino acid 
substitution at codon 474 (Leu474Phe) of the protein 
[17]. Hence, in people who carry the mutation, the NHL 
risk might be higher than those without the mutation.
To date, many studies have investigated the association 
between SHMT1 C1420T polymorphism and NHL risk, 
but the conclusions are mixed rather than conclusive, 
partially because of possible weak effects of the polymor-
phisms on NHL risk, the relatively small sample size in 
each previous investigation, or the patients’ diverse racial 
backgrounds. Therefore, we developed a comprehensive 
meta-analysis of all eligible case–control studies to derive 
a more precise risk estimate for the association.
Methods
Literature search strategy
We searched two electronic databases (PubMed and 
Embase) to identify all published studies with the fol-
lowing terms: “SHMT”, “SHMT1”, or “cytosolic serine 
hydroxymethyltransferase”, “polymorphism” or “variant”, 
“non-Hodgkin lymphoma” or “NHL”, and “cancer”, “neo-
plasia”, or “malignancy” (last search date: August 1, 2015). 
To expand the scope of our search, we also searched the 
Chinese National Knowledge Infrastructure database 
(CNKI) with the terms “SHMT”, “SHMT1”, and ‘‘NHL’’ in 
Chinese. Furthermore, we manually searched reference 
lists on this topic to identify additional relevant studies 
and attempted to contact the authors for more informa-
tion if the information available was incomplete.
Selection criteria
The studies selected in this meta-analysis had to meet 
the following criteria: (1) be written in English or Chi-
nese; (2) have a case–control design; (3) evaluate the 
association between SHMT1 C1420T polymorphism and 
NHL risk; and (4) provide sufficient data for the calcula-
tion of odds ratios (ORs) and 95% confidence intervals 
(CIs). Abstracts and unpublished reports were excluded. 
Moreover, if studies had the same subjects or overlapping 
data, we selected the one with the largest sample size.
Data extraction
Two reviewers independently abstracted the follow-
ing information from each study according to standard-
ized criteria: first author, year of publication, country of 
population studied, ethnicity of population studied, NHL 
subtype (DLBCL or FL), source of controls (population-
based, hospital-based, or mixed), total number of geno-
typed cases and controls, and numbers of genotypes (CC, 
CT, and TT) for the C1420T polymorphism in cases and 
controls. If any different views existing, we discussed it 
until consensus was reached.
Statistical methods
We used the crude ORs and 95% CIs to determine the 
association between SHMT1 C1420T polymorphism 
and NHL risk under different genetic models as follows: 
allelic comparison (T vs. C), homozygote model (TT vs. 
CC), heterozygote model (CT vs. CC), recessive model 
(TT vs. CC+CT), and dominant model (CT+TT vs. 
CC). Additionally, we performed stratification analyses 
by tumor subtype (DLBCL and FL) and by patient eth-
nicity (Caucasian and mixed; if the genotyping data listed 
in one article were for a mixture of different populations, 
this article was marked as “mixed” ethnicity). Goodness-
of-fit Chi-square test was used to evaluate deviation from 
the Hardy–Weinberg equilibrium (HWE) for the geno-
types of controls. The Chi-square-based Q test was per-
formed to calculate inter-study heterogeneity. If P < 0.05, 
we used the random-effects model to assess the pooled 
ORs because this model tends to provide wider 95% CIs 
[18]; otherwise, we used the fixed-effects model [19]. 
Furthermore, we conducted sensitivity analyses to eval-
uate the influence of individual studies on NHL risk by 
excluding one study sequentially each time and recalcu-
lating the pooled ORs and their 95% CIs. Moreover, pub-
lication bias was examined by the inverted funnel plot 
and the Egger test, and an asymmetric plot or P < 0.05 as 
determined by the Egger test was considered statistically 
significant [20]. All analyses were performed using the 
Review Manager software version 5.2.22.0 (The Nordic 
Cochrane Centre, The Cochrane Collaboration, London, 




After initial screening, we found 47 relevant publica-
tions. We excluded 38 of these studies after reviewing 
the titles and abstracts (6 were review articles, 3 were 
not case–control studies, 28 were not about the SHMT1 
Page 3 of 10Wang et al. Chin J Cancer  (2015) 34:60 
polymorphism, and 1 was in a language other than Eng-
lish or Chinese), and 9 articles were left for full review. 
Of these, 1 study was excluded for not providing geno-
type frequencies of NHL [21]. Eventually, 8 studies met 
our inclusion criteria; these studies covered 3232 NHL 
cases and 4077 controls, all of which were included in our 
pooled analyses [22–29] (Fig. 1). Table 1 lists the essen-
tial characteristics for all included studies. Of the 8 stud-
ies included, only 5 examined the association between 
the SHMT1 C1420T polymorphism and the subtype of 
NHL risk [22, 23, 25, 26, 29]. Of these 5 studies, 4 stud-
ies [22, 23, 25, 26] with 744 cases included 2353 controls 
for the DLBCL subtype, and 5 studies [22, 23, 25, 26, 29] 
with 778 cases included 2558 controls for the FL sub-
type. Additionally, 6 studies were conducted in Caucasian 
patients; the remaining 2 studies were conducted in 
patients from mixed ethnic groups. All studies were 
population-based designed; 7 studies of genotype distri-
bution in the controls were in line with HWE except the 
study conducted by Li et al. [28].
Quantitative synthesis
The primary results of this meta-analysis are presented 
in Table  2 and Figs.  2, 3, 4, 5, 6 and 7. In the pooled 
analysis, we found a statistically significant association 
between SHMT1 C1420T polymorphism and NHL risk 
under the allelic comparison (T vs. C: OR = 1.09, 95% CI 
1.01–1.17); we found a borderline association between 
SHMT1 C1420T polymorphism and NHL risk under 
the homozygote model (TT vs. CC: OR =  1.18; 95% CI 
1.00–1.39) and under the dominant model (CT+TT vs. 
CC: OR = 1.10; 95% CI 1.00–1.21). In the subgroup anal-
ysis by ethnicity, we found no association for Caucasians 
but a borderline direct association for mixed ethnic sub-
groups under the allelic comparison (T vs. C: OR = 1.13; 
95% CI 1.00–1.28) and the dominant model (CT+TT vs. 
CC: OR = 1.18; 95% CI 1.00–1.39).    
After excluding the study by Li et al. [28] because the 
genotype frequencies in the controls deviated from 
HWE, we conducted further analysis and determined 
that the positive result was converted into a negative one. 
No significant association was found in the stratification 
analysis by tumor subtype.
We calculated statistical power to detect an OR of 
1.50 for a risk effect, with a level equal to the observed P 
value. We further used the false-positive report probabil-
ity (FPRP) with prior probabilities of 0.0001, 0.001, 0.01, 
0.1, and 0.25 to account for chance associations from 
multiple comparisons (Table  3). Results with an FPRP 
value less than 0.20 were considered significant associa-
tions [30].
Fig. 1 Flow diagram of studies included in this meta‑analysis. CNKI 
China National Knowledge Infrastructure, SMHT1 serine hydroxym‑
ethyltransferase 1 and NHL non‑Hodgkin lymphoma
Table 1 Characteristics of the 8 publications included in the meta-analysis
USA the United States of America, HWE Hardy–Weinberg equilibrium, MAF minor allele frequency
a Each study is presented as the first author’s last name followed by the year of publication
b Mixed: in the study, the genotyping data were mixed from different ethnic populations
Studya Country Ethnicity Source of controls Sample sizes  
(cases/controls)
HWE (controls) MAF
Skibola (2004) [22] USA Caucasian Population‑based 333/729 0.509 0.32
Lightfoot (2005) [23] USA Caucasian Population‑based 589/754 0.181 0.32
Lee (2007) [24] Australia Caucasian Population‑based 553/498 0.129 0.32
Lim (2007) [25] USA Mixedb Population‑based 743/629 0.283 0.31
Berglund (2009) [26] Sweden Caucasian Population‑based 258/241 0.630 0.32
Weiner (2011) [27] Russia Caucasian Population‑based 141/504 0.357 0.33
Li (2013) [28] USA Mixedb Population‑based 446/517 0.044 0.30
Niclot (2006) [29] France Caucasian Population‑based 169/205 0.547 0.31
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Fig. 2 Forest plot for NHL risk associated with the SHMT1 C1420T polymorphism under the0020allelic comparison (T vs. C), stratified by ethnic‑
ity. A significant association was detected between the SHMT1 C1420T polymorphism and NHL risk under the allelic comparison. The boxes and 
horizontal lines correspond to the estimates of odds ratio (OR) and 95% confidence interval (CI) for each study. The diamond indicates the pooled OR 
and 95% CI
Fig. 3 Forest plot for NHL risk associated with the SHMT1 C1420T polymorphism under the homozygote model (TT vs. CC), stratified by ethnic‑
ity. A borderline association was detected between the SHMT1 C1420T polymorphism and NHL risk under the homozygote model. The boxes and 
horizontal lines correspond to the estimates of OR and 95% CI for each study. The diamond indicates the pooled OR and 95% CI
Page 6 of 10Wang et al. Chin J Cancer  (2015) 34:60 
Fig. 4 Forest plot for NHL risk associated with the SHMT1 C1420T polymorphism under the dominant model (CT+TT vs. CC), stratified by ethnicity. 
A borderline association was detected between the SHMT1 C1420T polymorphism and NHL risk under the dominant model. The boxes and horizon-
tal lines correspond to the estimates of OR and 95% CI for each study. The diamond indicates the pooled OR and 95% CI
Fig. 5 Forest plots for NHL risk associated with the SHMT1 C1420T polymorphism, stratified by NHL type (T vs. C). No significant association was 
detected in the stratification analysis by NHL subtype. The boxes and horizontal lines correspond to the estimates of OR and 95% CI for each study. 
The diamond indicates the pooled OR and 95% CI
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Fig. 6 Forest plots for NHL risk associated with the SHMT1 C1420T polymorphism, stratified by NHL type (TT vs. CC). No significant association was 
detected in the stratification analysis by NHL subtype. The boxes and horizontal lines correspond to the estimates of OR and 95% CI for each study. 
The diamond indicates the pooled OR and 95% CI
Fig. 7 Forest plots for NHL risk associated with the SHMT1 C1420T polymorphism, stratified by NHL type (CT+TT vs. CC). No significant association 
was detected in the stratification analysis by NHL subtype. The boxes and horizontal lines correspond to the estimates of OR and 95% CI for each 
study. The diamond indicates the pooled OR and 95% CI. DLBCL diffuse large B‑cell lymphoma and FL follicular lymphoma
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Heterogeneity and sensitivity analyses
No significant between-study heterogeneities were 
observed among the overall studies for the associa-
tion of SHMT1 C1420T polymorphism with NHL 
risk (allelic comparison: P  =  0.29; homozygote model: 
P = 0.07; dominant model: P = 0.65; heterozygote model: 
P =  0.64), except for the recessive model (P =  0.04). In 
the sensitivity analyses, the results indicated that a single 
study might change the pooled ORs (data not shown).
Publication bias
Begg’s funnel plot and the Egger test were used to evalu-
ate the publication bias of all included studies. The shapes 
of the funnel plots appeared to be symmetrical, and the 
Egger test further suggested that there was no signifi-
cant evidence of publication bias under some genetic 
models (allele comparison: P = 0.83; homozygote model: 
P  =  0.39; dominant model: P  =  0.29; recessive model: 
P = 0.23), but the heterozygote model showed significant 
publication bias (P = 0.02).
Discussion
Our meta-analysis, which examined eight studies encom-
passing 3232 NHL cases and 4077 controls, investigated 
the association between SHMT1 C1420T polymorphism 
and NHL risk. A borderline association was detected, 
which indicated that this polymorphism may increase 
NHL risk, although the effect of the SNP was very weak.
SHMT1 is a key enzyme in the folate metabolic path-
way and supplies one-carbon molecules to the cycle; 
this carbon plays an important role in the biosynthesis 
of purine, thymidylate, and methionine [12], which are 
essential for DNA synthesis and gene methylation. There-
fore, the 1420 C>T polymorphism in SHMT1 creates an 
imbalance in folate metabolism, which adversely affects 
DNA synthesis and methylation systems and causes 
genome instability, eventually leading to overexpres-
sion of oncogenes and inactivation of tumor suppressor 
genes [13, 14]. Additionally, the polymorphism can cause 
reduced circulating folate levels [23], which not only 
shunts 5,10-methylenetetrahydrofolate toward DNA 
synthesis but also results in uracil misincorporation into 
DNA, eventually leading to double-strand breaks, chro-
mosomal damage, and cancer [31, 32].
We found that SHMT1 C1420T might have a weak 
effect on NHL risk. There are several possible explana-
tions for this result. First, because only eight studies met 
our review criteria, the sample size of the meta-analysis 
was not large enough to detect a specific effect on NHL 
risk. Second, the cancer risk conferred by the genetic 
variation is indeed very modest, and the penetrance is 
very small for the variants. Third, other causal genes, 
which are implicated in the pathogenesis of cancer, might 
mask the effect of SHMT1 C1420T polymorphisms by 
gene–gene interactions and, consequently, modulate can-
cer susceptibility. In any case, studies with larger sample 
sizes are warranted to validate our findings.
In the stratifying analysis by ethnicity, we found that 
SHMT1 C1420T polymorphism might be associated 
with an increased NHL risk in the mixed ethnic group 
but not in the Caucasian group, suggesting that there 
are some differences in genetic information of individ-
uals from different races. In addition, the possibility of 
misinformation was not ruled out. However, because 
of the small sample size of the mixed ethnic subgroup, 
this result remains questionable, and additional studies 
with larger sample sizes are needed. To date, only one 
meta-analysis, which was published in 2011 [26], has 
focused on the association between SHMT1 C1420T and 
NHL risk. After examining eight studies that encom-
passed 2884 cases and 4054 controls, Weiner et al. [27] 
concluded that SHMT1 C1420T had no effect on the 
risk of NHL, which was inconsistent with the results of 
our study. Have been examined carefully, we found that 
the meta-analysis by Weiner et  al. [27] included one 
study by Hishida et  al. [33] that we excluded because 
Table 3 False-positive report probability values and  statistical power for  associations between  genotypes of  SHMT1 
C1420T polymorphism and NHL risk
Abbreviations as in Tables 1 and 2
a The OR reported in Table 2
b Genotype frequency distributions were calculated using the omnibus Chi-square test in Table 2
c Statistical power was calculated using the number of observations (cases and controls) and the OR and P values in Table 2
Genotype Positive OR  
(95% CI)a
P valueb Statistical  
powerc
Prior probability
0.25 0.10 0.01 0.001 0.0001
SHMT1 C1420T
 T vs. C 1.09 (1.01–1.17) 0.025 1.000 0.070 0.184 0.712 0.962 0.996
 TT vs. CC 1.18 (1.00–1.39) 0.046 0.999 0.121 0.293 0.820 0.979 0.998
 CT+TT vs. CC 1.10 (1.00–1.21) 0.054 0.820 0.165 0.372 0.867 0.985 0.999
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it provided the data about malignant lymphoma rather 
than NHL. In addition, we added one more study [29] 
in our meta-analysis to enlarge the sample size and 
improve the statistical power. Therefore, compared with 
the meta-analysis by Weiner et al. [27], our study derives 
a more precise risk estimate for the association between 
SHMT1 C1420T polymorphism and NHL risk. Further-
more, we put all the studies together to collectively ana-
lyze and then draw a conclusion. Although researchers 
commonly pool data from different cancer subtypes, it 
is unclear whether the association of genetic variation 
with risk of cancer should be calculated this way. We 
used this approach because many studies have discov-
ered that some sequence variants in specific regions of 
chromosomes, such as 17p11.2, are associated with risk 
of specific subtypes of cancer [28, 34]. We speculate that 
the SNP may be the specific site associated with different 
NHL subtypes.
Our meta-analysis has several limitations. First, the 
results of these sensitivity analyses indicated that a single 
study might change the pooled ORs, which means that 
our results may have low robustness and should be inter-
preted cautiously. Second, selection bias resulted from 
the fact that only studies written in English or Chinese 
were included in this meta-analysis. Third, the sample 
size of the included studies was relatively small, especially 
in the stratified analysis, which may result in limited sta-
tistical power. Fourth, significant heterogeneity in the 
meta-analysis was observed under the recessive model. 
We did not deem lightly the issue of the random-effects 
model used to incorporate heterogeneity among stud-
ies. Further stratification analysis suggested that ethnic-
ity may be the main source of heterogeneity. Moreover, 
there is other heterogeneity that cannot be explained. 
Fifth, because more detailed information was not availa-
ble in the included studies, possible compounding factors 
(such as age and sex) could not be obtained for stratifica-
tion analysis to further evaluate the relationship between 
SHMT1 polymorphism and NHL risk. Sixth, because 
all included studies were case–control, this may have 
caused selection bias, implementation bias, and con-
founding bias because of the nature of retrospective stud-
ies. Finally, in terms of publication bias, the funnel plot’s 
power is relatively low when fewer than 30 publications 
are tested for asymmetry. Moreover, most of the data on 
publication bias are retrospective rather than prospec-
tive, including our current analysis. Reporting publica-
tion bias from prospective studies is necessary.
In summary, we found in this updated meta-analysis 
that SHMT1 C1420T polymorphism may be a risk fac-
tor for NHL. Additional well-designed studies with larger 
sample sizes and more information about confounding 
factors are needed to validate our findings.
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